Home / Pharmaceutical / The Pharmaceutical Market: The Netherlands

The Pharmaceutical Market: The Netherlands

Published: Nov 2015 | No Of Pages: 114 | Published By: Espicom

Product Synopsis

 
OVERVIEW OF THE PHARMACEUTICAL MARKET IN THE NETHERLANDS
 
While the Netherlands is a low-risk market from the point of view of multinational drugmakers, the country's modest per capita expenditure on pharmaceuticals relative to other Western European countries is an issue. Another challenge facing drugmakers is cost-containment, which will only intensify as the Netherlands enters a period of slower economic growth. In fact, as we warned , the Dutch authorities recently introduced a new scheme - reimbursement for medicines that prove therapeutically ineffective will be reclaimed from the manufacturer - to reduce public healthcare costs. BMI notes that the 'no cure, no pay' scheme implemented by the Dutch government is not a new concept , with t he US government and a number of Western European governments already having made risk - sharing or money-back guarantee agreements with drug companies. However, these agreements focused on particular medicines, unlike the much harsher 'blanket' stance of the Dutch health ministry.
 
Headline Expenditure Projections
  • Pharmaceuticals: EUR6.70bn (US$9.31bn) in 2011 to EUR6.51bn (US$8.27bn) in 2012; -2.8% in local currency terms and -11.2% in US dollar terms. Forecastunchanged from Q4 12.
  • Healthcare: EUR62.94bn (US$87.49bn) in 2011 to EUR64.43bn (US$81.83bn) in 2012; +2.4% in local currency terms and -6.5% in US dollar terms. Forecastunchanged from Q4 12.
  • Medical devices: EUR11.41bn (US$15.86bn) in 2011 to EUR11.72bn (US$14.89bn) in 2012; +2.8% in local currency terms and -6.1% in US dollar terms. Forecastunchanged from Q4 12.
Competitive Landscape
 
The competitive landscape section provides comparative company analyses and rankings by US$ sales and % share of total sales - for the total pharmaceutical sector, as well as the OTC, generics, and distribution sub-sectors.
BMI Industry View7
SWOT9
Political11
Economic12
Business Environment13
Industry Forecast14
Pharmaceutical Market Forecast14
 
Table: Pharmaceutical Sales, Historical Data And Forecasts (Netherlands 2010-2018)16

Healthcare Market Forecast16
 
Table: Healthcare Expenditure Trends, Historical Data And Forecasts (Netherlands 2010-2018)19
Table: Government Healthcare Expenditure Trends, Historical Data And Forecasts (Netherlands 2010-2018)19
Table: Private Healthcare Expenditure Trends, Historical Data And Forecasts (Netherlands 2010-2018)19
 
Prescription Drug Market Forecast20
 
Table: Prescription Drug Market Indicators, Historical Data And Forecasts (Netherlands 2010-2018)22
 
Patented Drug Market Forecast23
 
Table: Patented Drug Market Indicators, Historical Data And Forecasts (Netherlands 2010-2018)24
 
Netherlands24
 
Table: Generics Drug Market Indicators, Historical Data And Forecasts (Netherlands 2010-2018)26
 
OTC Medicine Market Forecast26
 
Table: OTC Medicine Sales Indicators By Category, 2008-201028
Table: Over-The-Counter (OTC) Medicine Market Indicators, Historical Data And Forecasts (Netherlands 2010-2018)29
 
Pharmaceutical Trade Forecast30
 
Table: Pharmaceutical Trade Data And Forecast (Netherlands 2012-2018)31
Table: Pharmaceutical Trade Data And Forecasts local currency (Netherlands 2012-2018)31
 
Other Healthcare Data32
 
Table: Number Of Physicians By Type, 2007-201033
 
Key Risks To BMI's Forecast Scenario33
Macroeconomic Forecasts35
Economic Analysis35
 
Table: Netherlands - Economic Activity38
 
Industry Risk Reward Ratings39
Western Europe Risk/Reward Ratings39
Netherlands Risk/Reward Ratings44
Rewards44
Risks44
Market Overview46
Industry Trends And Developments47
Epidemiology47
Healthcare Sector48
Healthcare Funding50
Health Insurance51
 
Table: Key Points Of The Dutch Health Insurance Act, January 1 200652
 
Healthcare Insurance Developments56
 
Table: Biosimilars Approved In The EU57
 
Research And Development57
Clinical Trials60
Biotechnology63
Regulatory Development64
Regulatory Developments65
Intellectual Property Regime67
Pricing Regime68
Reimbursement Regime70
Competitive Landscape73
Pharmaceutical Industry73
 
Table: Pharmaceutical Production, 1995-2010 (EUR '000s)73
 
Recent Company Activity75
Pharmaceutical Wholesale Sector77
Pharmaceutical Retail Sector78
Company Profile81
DSM81
Qiagen85
Pharming Group88
Merck & Co92
Pfizer95
GlaxoSmithKline98
Sanofi100
Novartis102
Demographic Forecast105
Demographic Outlook105
 
Table: The Netherlands' Population By Age Group, 1990-2020 ('000)106
Table: The Netherlands' Population By Age Group, 1990-2020 (% of total)107
Table: The Netherlands' Key Population Ratios, 1990-2020108
Table: The Netherlands' Rural And Urban Population, 1990-2020108
 
Glossary109
Methodology111
Pharmaceutical Expenditure Forecast Model111
Healthcare Expenditure Forecast Model111
Notes On Methodology112
Risk/Reward Ratings Methodology113
Ratings Overview114
 
Table: Pharmaceutical Risk/Reward Ratings Indicators114
 
Indicator Weightings115
Choose License Type
 
Contact Information
24/7 Research Support
Phone: +1-855-455-8662
sales@acutemarketreports.com
Get in Touch with us
join us on Facebook
Follow us on Twitter
Follow us on LinkedIn
Add us on Google +